Astellas changes management structure

Not satisfied with simply changing personnel, Japanese drugmaker Astellas (TYO: 4503) has announced a new management structure, effective April 1.

The Tokyo-based company has said that the rejigged setup will promote drug discovery activities swiftly and efficiently from the early stages of research through to commercialization with a patient-centric approach.

Roles that are to be eliminated are those of the chief medical, scientific and commercial officers, with their duties now to be shared by the holders of two newly-created positions, chief R&D officer and chief commercial and medical affairs officer (CCMAO).